Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in primary IgA nephropathy
NCT06830395Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in IgA nephropathy (IgAN), sponsored by Keymed Biosciences. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cm313
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06830395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830395.